Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: AGL
Market: AIM
52-week High/Low: 80.00p / 32.27p
Sector: Pharma & Biotech
Market Cap: 31.42M
Website: www.angleplc.com
ANGLE plc

ANGLE plc

ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health.

ANGLE plc’s lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalised cancer care.

ANGLE plc has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA approval process is underway for the clinical market in the US.

ANGLE plc

www.angleplc.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in ANGLE plc


Cancer cells
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample

ANGLE plc Snapshot

ANGLE has a clear strategy to commercialise its Parsortix technology.

 

The cell capture and harvesting technology consists of a cell separation cassette together with an automated system to run blood samples through the cassette. There is extensive intellectual property protection around key elements of the system.

 

Successful evaluation of the system by major cancer research centres has already been achieved and a major part of ANGLE’s current efforts relate to further deployment with key opinion leaders in the field.

 

Regulatory authorisation for the clinical use of the system in patient treatment in the EU has already been achieved and the process is ongoing with the FDA for the USA.

 

Widespread adoption of the Parsortix system in the clinical market crucially depends on ongoing work with key opinion leaders to:

 

  • Undertake pilot studies assessing clinical applications for CTCs. Select the most promising applications
  • Undertake larger patient studies providing fully documented evidence of how the system should be used for particular patient applications in routine treatment
  • Convert key opinion leader support and peer reviewed publications into widespread adoption of the Parsortix system in routine patient care

 

The problem and need

 

Cancer Research UK‘s statistics suggest that men have a 45% likelihood of suffering cancer during their life. Women are only slightly lower at 41%.

 

During treatment for the disease, particularly secondary (metastatic) disease, there are a number of challenges, including:

 

  • How does the clinician know which drug will work most effectively on a patient?
  • How does the clinician track whether drugs are in fact working and having a positive impact?
  • How do clinicians monitor patients who are in remission to pick up any return of disease?

 

The above treatment challenges can be complicated further with the fact that the form of the disease can evolve over time meaning that a drug that would not have been effective at one point, may at a later point turn out to be effective.

 

In order to treat patients effectively, doctors need to deploy drugs that target the individual patient’s cancer at that point in time. This approach is called “personalised cancer care” and in recent years has become accepted worldwide as the most likely way to improve patient outcomes in the long run.

 

There is therefore a crucial need for ongoing information as to a patient’s cancer status. Primary tumors will be completely removed if possible and hence repeat biopsy is not an option. Biopsy of secondary disease sites tends to be far more difficult, is invasive and costly.

 

Circulating Tumor Cells and the Parsortix solution

 

Solid tumor cancers, such as breast cancer and prostate cancer, shed cancer cells into the patient’s blood stream.

These are cells are known as Circulating Tumor Cells (CTCs). CTCs are very rare, perhaps a single cell in one billion blood cells, and as a result are very difficult to isolate. They are however extremely valuable cells since

  • They contain information on the type of disease – which has the potential to inform on “personalised” care decisions and targeted drug therapies
  • Their presence and quantity has been shown to be indicative of patient prognosis
  • They are very likely to be the route by which primary (localised) tumors spread around the body so resulting in metastatic disease.

 

The Parsortix system from ANGLE is able to capture and harvest CTCs from patient blood. This means that a simple peripheral blood test could be used to provide crucial medical information regarding the changing status of a patient’s disease.

 

It is widely agreed that such a “liquid biopsy” would have a profound impact in understanding the patient’s current cancer status and ensuring the optimum treatment is deployed for that individual patient at that particular time.

 

Market size

 

ANGLE’s ultimate objective is the widespread adoption of the Parsortix system in the diagnosis and treatment of cancer patients. According to the World Health Organisation, there were an estimated 14 million new cancer cases worldwide in 2012, a marked rise on the 12.7 million cases in 2008.  In 2012, there were an estimated 32.6 million people living with cancer.  (Source: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)

 

The incidence of cancer continues to grow as a result of demographic, lifestyle and environmental factors and it is estimated that one in three people in the UK will get cancer during their lifetime.

 

There are a wide range of potential applications for harvested CTCs including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness, and remission monitoring. We estimate that this represents a potential global market for ANGLE’s Parsortix system worth in excess of £8 billion per annum.

 

ANGLE’s major focus is on the cancer market.  There is also a substantial market available in non-invasive foetal diagnostics, harvesting foetal cells from the pregnant mother and analysing for Down’s Syndrome and many other chromosomal and genetic conditions through a simple blood test.

 

Garth Selvey

Garth Selvey

Non Executive Chairman

Garth Selvey has a BSc in Physics and Electronics Engineering from the University of Manchester and has spent thirty six years in the computer industry with technical, product, sales and marketing roles. He became Managing Director of TIS Applications Ltd in 1984 and a main board director of TIS Ltd prior to its acquisition by Misys in 1989. He organised the management buyout of the social housing division of Misys and became Group Chief Executive of Comino Group plc when it floated on AIM in 1997. Comino moved to a full listing in 1999 where he remained until its successful public sale to Civica plc in February 2006. Garth joined ANGLE as a Non-executive Director in September 2006.

Andrew Newland

Andrew Newland

Chief Executive

Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant. After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he led KPMG’s involvement in the IPO of the medical technology
company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG’s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in 1994. Together with ANGLE’s senior management team, Andrew has co-founded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of dstl Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.

Ian Griffiths

Ian Griffiths

Finance Director

Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work. He joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures, both third party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic business Parsortix.

Brian Howlett

Brian Howlett

Non Executive Director

Brian Howlett has a wealth of international experience as a medtech leader which he is currently applying in a Non-Executive / Chairman capacity for surgical graft company Vascular Flow Technologies Ltd, skin cancer imaging company Michelson Diagnostics Ltd and medical device coating and surface modification company Accentus Medical Ltd, as well as ANGLE plc. Brian was formerly CEO of Lombard Medical Technologies PLC, an AIM listed company specialising in stents for abdominal aortic aneurysms from 2005 to 2009. During his tenure significant capital was raised to fund the development of operations to commercialise the Aorfix stent graft towards regulatory approvals and growing revenues in EU, USA, Russia and Brazil. Corporate experience includes six years as UK Country Leader of Boston Scientific Ltd, between 1999 and 2005, during which time major medical devices such as the TAXUS drug eluting stent were launched driving sales and profits to the point where the UK and Ireland subsidiary became one of the leading revenue contributors to the Corporation’s European operations. Between 1987 and 1999, Brian was Managing Director of the UK sales and manufacturing subsidiary of Cobe Laboratories Inc. In addition, Brian spent almost 20 years in the pharmaceutical industry, gaining strong sales and marketing experience through a number of senior management positions in UK, Scandinavia and the Benelux markets within Fisons plc. Brian joined ANGLE as a Non-executive Director in January 2013.

 

ANGLE plc

3 Frederick Sanger Road

The Surrey Research Park

Guildford

Surrey

GU2 7YD

United Kingdom T   +44 (0)1483 685830 

F   +44 (0)1483 685836 

E   enquiries@angleplc.com

 

Auditors

RSM UK Audit LLP (formerly Baker Tilly)

One London Square Cross Lanes

Guildford

Surrey

GU1 1UN T

+44 (0)1483 307000

Nominated Advisor and Broker

Cenkos Securities plc

6.7.8 Tokenhouse Yard

London

EC2R 7AS T

+44 (0)20 7397 8900

Bankers

NatWest Bank

PO Box 1 2nd Floor,

G3 2 Cathedral Hill

Guildford

Surrey

GU1 3ZR T

+44 (0)1483 739540 

Solicitors / Lawyers

Pinsent Masons

30 Crown Place

Earl Street

London

EC2A 4ES T

+44 (0)207 418 7000 

Financial Public Relations

F T I Consulting

200 Aldersgate

London

EC1A 4HD

T +44 (0)20 3727 1390 

Registrars Registrar

Capita Registrars

The Registry

34 Beckenham Road

Beckenham

Kent

BR3 4TU T

+44 (0)871 664 0300  (Calls cost 10p per minute plus network extras) F +44 (0)208 639 2342

 

ANGLE plc Timeline

Columns Including AGL

VIEW ALL

Market Reports Including AGL

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use